Foroughi-Nia Behrouz, Barar Jaleh, Memar Mohammad Yousef, Aghanejad Ayuob, Davaran Soudabeh
Department of Medicinal Chemistry, Faculty of Pharmacy, Tabriz University of Medical Sciences, Tabriz, Iran; Research Center for Pharmaceutical Nanotechnology, Biomedicine Institute, Tabriz University of Medical Sciences, Tabriz, Iran.
Research Center for Pharmaceutical Nanotechnology, Biomedicine Institute, Tabriz University of Medical Sciences, Tabriz, Iran; Department of Pharmaceutics, Faculty of Pharmacy, Tabriz University of Medical Sciences, Tabriz, Iran.
Life Sci. 2021 Aug 1;278:119642. doi: 10.1016/j.lfs.2021.119642. Epub 2021 May 24.
Tyrosine kinase inhibitors (TKIs), as an important class of chemotherapeutic drugs, induce apoptosis by altering the path of the cellular signal, resulting in cell death. However, some chemotherapeutic drugs have a limited therapeutic index and are usually destructive as well as unpredictable. In addition, the limitation of early diagnosis and inefficiency of some of the drugs in ordinary treatments lead to disease progression and decreases in the survival of cancer patients. For this purpose, various methods have been proposed, among them, nanomedicine has transpired as a modern approach for the treatment of multiple cancers. Over the last two decades, targeted therapy has been developed for cancer-specific cells/tissues and has rather restricted nonselective toxicities. In vivo and in vitro studies demonstrated nanoparticles (NPs), nano-scale drugs, and nano-carriers alone or in combination with other therapeutic, imaging, and theranostic agents would be applied as an effective approach targeting a diversity of malignant tissue. Therefore, using the latest advances in materials science and biomaterials, biology, it has happened that general diagnosis and treatment can be performed. In this review, we indicated the applications of theranostic nano-polymer and nano-liposome to TKIs delivery.
酪氨酸激酶抑制剂（TKIs）作为一类重要的化疗药物，通过改变细胞信号通路诱导细胞凋亡，从而导致细胞死亡。然而，一些化疗药物的治疗指数有限，通常具有破坏性且不可预测。此外，早期诊断的局限性以及某些药物在常规治疗中的低效性导致疾病进展和癌症患者生存率下降。为此，人们提出了各种方法，其中，纳米医学已成为一种治疗多种癌症的现代方法。在过去二十年中，针对癌症特异性细胞/组织开发了靶向治疗，并且相当程度地限制了非选择性毒性。体内和体外研究表明，纳米颗粒（NPs）、纳米级药物和纳米载体单独或与其他治疗、成像和诊疗剂联合使用，将作为一种针对多种恶性组织的有效方法。因此，利用材料科学和生物材料、生物学的最新进展，已经能够实现一般的诊断和治疗。在本综述中，我们阐述了诊疗纳米聚合物和纳米脂质体在TKIs递送中的应用。
